Joseph Alvarado

发表

Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro)

Alice Hooper, C. Goins, S. Han, 2021, Journal of medicinal chemistry.

Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dihydroisoquinolinone bicyclic core

S. Fesik, R. Coffey, J. Sai, 2020 .

WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma

Patrick J. Paddison, Lisa C. Wallace, Anoop P. Patel, 2021, bioRxiv.

Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design.

E. Olejniczak, S. Fesik, O. Rossanese, 2018, Journal of medicinal chemistry.

Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation

E. Klein, N. Sabharwal, C. Goins, 2021, Science Translational Medicine.

Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization.

S. Fesik, J. Sai, Bin Zhao, 2022, Journal of medicinal chemistry.

Discovery and Structure-Based Optimization of Potent and Selective WD repeat domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.

S. Fesik, R. Coffey, M. Inoue, 2019, Journal of medicinal chemistry.

Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity

S. Fesik, M. Hall, Qi Liu, 2019, Cell reports.

Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Protein-Protein Interaction.

S. Fesik, A. Waterson, O. Rossanese, 2019, Journal of medicinal chemistry.

WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma

Lisa C. Wallace, Anoop P. Patel, Tyler E. Miller, 2023, Genes & Development.